Navigation Links
Draft National Policy on Sight-saving Drugs unacceptable

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is unacceptable concludes the July issue of Drug and Therapeutics Bulletin (DTB).

But that is what the National Institute for Health and Clinical Excellence (NICE), the body responsible for guiding the NHS on which treatments to use, is proposing.

Ranibizumab (Lucentis) and pegaptanib (Macugen) are licensed in the UK for the treatment of neovascular (wet) age-related macular degeneration. A third drug bevacizumab (Avastin) is also used, but not licensed for the condition.

In wet age-related macular degeneration, in which fine central vision is progressively lost, new blood vessels grow beneath the retina, a process stimulated by vascular endothelial growth factor (VEGF). All three drugs potentially block the effects of VEGF.

Wet age-related macular degeneration is the third most common cause of blindness worldwide. It affects around 2.3% of over-65s in Europe. In the UK around 26,000 people develop it each year and 245,000 are blind or visually impaired because of it.

After a thorough examination of published clinical trial data, DTB concludes that there is good evidence that both ranibizumab and pegaptanib prevent further deterioration in vision in most patients. Ranibizumab improved vision in a third.

The NICE draft guidance on use of ranibizumab and pegaptanib was published in June. It recommends ranibizumab for only about 20 per cent of patients with wet age-related macular degeneration, restricting its use to those in whom both eyes are affected and then to the better seeing eye.

Final guidance is due in September.

DTB says: We believe that policies that dictate that patients must go blind in one eye before being given treatment for the other are unacceptable.

It continues: Pegaptanib and ranibizumab need to be made available for use thr oughout the NHS, as is the case in Scotland. In the absence of such national arrangements elsewhere in the UK, NHS commissioners need to work with local clinicians to ensure that the benefits of these drugs are made available to as many patients as possible.

NICE has not issued draft guidance on bevacizumab, but many primary care trusts recommend its use because it is cheaper than pegaptanib and ranibizumab.

DTB says that bevacizumab might provide a lower cost alternative, but cautions that there is as yet no robust evidence of its safety and effectiveness in the treatment of macular degeneration. Therefore, we cannot recommend such use outside of clinical trials.


'"/>




Related medicine news :

1. OPPI Opposes Draft National Pharmaceuticals Policy
2. Smoking Ban Draft Is Put For Consultation
3. Kerala Drafts a New Health Tourism Policy
4. National Lung Study in the process
5. Indian Nationals with Foreign Medical Degrees can now practice in India
6. Hepatitis B Vaccine To Be Included In National Immunization Programme
7. UK Govt Says On Course For National Chlamydia Screening
8. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
9. India extends National TB Control Program
10. President and Founder of National Obesity Forum Resigns
11. Hwang Woo Suk Suspended By Seoul National University
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon Kleyne ... declared on her radio program in November 2016 the need to educate people about ... leaders in corporate America, they are trying to take advantage of successful algorithms and ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies and ... scam operations to a halt. According to Texas Premier Locksmith, these fraudulent locksmith ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on ... user experience. , BOC Global Events & Training Group is a professional event ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “Tomorrow Trump ... Donald Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes ... to do as much as she can for this country. , Nancy attributes her ...
(Date:12/7/2016)... Soquel, Caloifornia (PRWEB) , ... December 07, 2016 ... ... to present the fifth annual Business Architecture Innovation Summit in Reston, VA on ... the world who will share a range of experiences from a cross-section of ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to a new market research report "Clinical Decision ... Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, Passive), Application - ... reach USD 1,519.2 Million by 2021 from USD 856.3 Million in 2016, ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... Today, Stock-Callers.com presents four Biotech equities for review, ... Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi Therapeutics Inc. ... AVXS ). From its peak in July 2015, the ... level equal to what it saw at the start of ... year, it has still out-performed other market sectors, beating the ...
(Date:12/6/2016)... Dec. 6, 2016  Alopexx Oncology, LLC announced data ... antibody fusion protein (immunocytokine) composed of interleukin-2 and a ... target on B cells as Rituxan and maintains the ... is also involved in tumor targeting, engagement of the ... The results of the study (abstract #95954) were presented ...
Breaking Medicine Technology: